all american licensingpow


All American Licensing Packs A Punch As It

Signs Stan Lee’s POW! Entertainment


          AAL to License Stan Lee Brand to Multi-Tiered Retail Distribution Following Stan Lee’s POW! Entertainment’s recent announcement of upcoming projects 

Los Angeles, CA - August 1, 2019 – All American Licensing (AAL) has signed on with Stan Lee’s POW! Entertainment, Inc. to develop a comprehensive portfolio of uniquely branded products based on the global icon Stan Lee, including his name and likeness, signature, and famous catchphrases and trademarks, such as “Excelsior!”  

Stan Lee was the creator of many successful Marvel characters that have generated more than $25 billion in sales at retail. He was known as the “King of Cameos” with close to 100 appearances in movies and TV Shows.  Stan Lee has a growing fan base of close to 22 million followers on social media, and his name appears on over 2 billion books worldwide.

With new partners on board, including most recently Madame Tussauds, who is creating a brand-new Stan Lee figure which will officially debut in late 2019/early 2020 at either the London or New York locations, all Stan Lee-related merchandise creates $1 billion revenue annually.

Stan Lee’s POW! Entertainment has several unique style guides, which AAL will be offering to licensees in connection with the agency’s multi-tier licensing opportunities. 

Tim Rothwell, co-founding partner at All American Licensing, commented, “As a former president of Marvel Entertainment Consumer Products Group, we’ve appreciated the amazing global impact that Stan Lee has made on our licensing industry and All American Licensing is excited to continue with his legacy in the marketplace.” 

Gill Champion, Stan’s partner and loyal friend for over 18 years and President of Stan Lee’s POW! Entertainment since co-founding the company, said, “At Stan Lee’s POW! Entertainment, we don’t have a strategy – we have a mission and that is to ensure Stan’s iconic legacy lives on forever through his fans for generations to come. We’re thrilled to have partnered with the team at All American Licensing, and I have no doubt with their help we can achieve our mission.”

Solution Providers
rmsolution v58i6


  • SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participate in a fireside chat at the Barclays Global Healthcare Conference on Thursday, March 11, 2021, at 2:25 p.m. ET.

  • WALTHAM, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will not pursue additional development of APL-9, an investigational targeted C3 therapy designed for acute interventions, for the treatment of severe COVID-19. The decision followed an interim review of mortality data from the Phase 1/2 study by an independent data monitoring committee (DMC), which found no meaningful reduction in the overall mortality rate in patients treated with APL-9 in combination with standard of care therapy compared to standard of care alone. No safety signals were observed by the DMC.

  • BURLINGAME, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, and Tallac Therapeutics, Inc. (“Tallac”), a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced a collaboration to jointly develop, manufacture, and commercialize a novel class of cancer immunotherapeutics. Under the terms of the agreement, ALX Oncology and Tallac will share equally in the cost of research and development and any profits or losses incurred.

  • CARLSBAD, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter and year ended December 31, 2020, and recent corporate highlights.

  • SANTA MONICA, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update. 

Corporate Head Office

Retail Merchandiser Magazine

Cringleford Business Centre,
Intwood Road Cringleford,
Norwich, UK, NR6 4AU

 +44 (0) 1603 274 130

Click here for a full list of contacts.

North American office

Retail Merchandiser Magazine

Finelight Media,
207 E. Ohio Street Suite 351
Chicago, IL 60611

Click here for a full list of contacts.

Back To Top